Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of “Moderate Buy” by Analysts

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has been assigned an average rating of “Moderate Buy” from the nine brokerages that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, four have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $91.8333.

Several equities research analysts have issued reports on the stock. Guggenheim boosted their price objective on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Mizuho assumed coverage on shares of Tarsus Pharmaceuticals in a report on Thursday, November 20th. They set an “outperform” rating and a $100.00 target price on the stock. Wall Street Zen downgraded Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Zacks Research cut Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th.

Tarsus Pharmaceuticals Stock Performance

NASDAQ TARS opened at $68.24 on Thursday. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.85 and a quick ratio of 3.82. Tarsus Pharmaceuticals has a 1-year low of $38.51 and a 1-year high of $85.25. The firm has a market capitalization of $2.90 billion, a P/E ratio of -42.12 and a beta of 0.55. The business’s 50-day simple moving average is $69.59 and its 200-day simple moving average is $70.20.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%.The business had revenue of $151.67 million for the quarter, compared to analyst estimates of $144.56 million. Equities analysts predict that Tarsus Pharmaceuticals will post -3.17 EPS for the current year.

Insider Activity

In other news, Director William J. Phd Link sold 12,500 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $68.79, for a total transaction of $859,875.00. Following the sale, the director owned 116,332 shares in the company, valued at $8,002,478.28. This trade represents a 9.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Bobak R. Azamian sold 6,000 shares of the business’s stock in a transaction on Wednesday, December 24th. The stock was sold at an average price of $82.51, for a total transaction of $495,060.00. Following the transaction, the chief executive officer directly owned 857,991 shares in the company, valued at approximately $70,792,837.41. The trade was a 0.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 8.97% of the company’s stock.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TARS. Deep Track Capital LP lifted its holdings in Tarsus Pharmaceuticals by 71.4% in the 3rd quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock worth $178,290,000 after buying an additional 1,250,000 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of Tarsus Pharmaceuticals by 34.1% during the fourth quarter. Janus Henderson Group PLC now owns 1,930,325 shares of the company’s stock valued at $158,062,000 after acquiring an additional 491,326 shares in the last quarter. Norges Bank purchased a new stake in shares of Tarsus Pharmaceuticals during the second quarter worth about $19,095,000. M&T Bank Corp increased its position in shares of Tarsus Pharmaceuticals by 11,730.0% during the fourth quarter. M&T Bank Corp now owns 437,119 shares of the company’s stock worth $35,791,000 after acquiring an additional 433,424 shares during the last quarter. Finally, MPM Bioimpact LLC acquired a new position in shares of Tarsus Pharmaceuticals in the second quarter worth about $13,834,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.